Современное лечение псориатического артрита


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Выполнен анализ современных подходов к фармакотерапии псориатического артрита. Указано, что основной целью лечения заболевания является достижение ремиссии или минимальной активности его проявлений (артрита, спондилита, энтезита, дактилита, псориаза), другие цели: замедление рентгенологического прогрессирования, увеличение продолжительности и улучшение качества жизни пациентов, снижение риска развития коморбидных заболеваний. Рассмотрены подходы к лечению псориатического артрита с применением нестероидных противовоспалительных препаратов, внутрисуставных глюкокортикоидов, базисных противовоспалительных и генно-инженерных биологических препаратов. Обращено внимание на тот факт, что наиболее выгодное соотношение эффективности и переносимости характерно для метотрексата. Рассмотрены имеющиеся к настоящему времени сведения о возможностях и перспективах использования препаратов на основе моноклональных антител: ингибиторов фактора некроза опухоли и других интерлейкинов в лечении псориатического артрита.

Полный текст

Доступ закрыт

Об авторах

Т. В Коротаева

ФГБУ «НИИР им. В.А. Насоновой» РАМН

Email: tatianakorotaeva@gmail.com
д.м.н., с.н.с. отдела ранних артритов

Список литературы

  1. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment// Ann. Rheum. Dis. - 2010 - Vol. 69(1). - P. 48-53.
  2. Gladman D.D. Mortalityinpsoriaticarthritis//Clin. Exp. Rheumatol. - 2008. - Vol. 26(Suppl. 51). -P. 62-5.
  3. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies// Ann. Rheum. Dis. - 2012. - Vol. 71. - P. 4-12.
  4. Mease P.J. Measures of Psoriatic Arthritis. Arthritis Care & Research. 2011;11(63):64-85.
  5. Borer J.S., Simon L.S. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance // Arthritis Res. Ther. - 2005. - Vol. 7(Suppl. 4). - P. 14-22.
  6. Kivitz A.J., Espinoza L.R., Sherrer Y.R., et al. A comparison of the eficacy and safety of cele-coxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis //Semin. Arthritis Rheum. - 2007. -Vol. 37. - P. 164-73.
  7. Soriano E., McHugh N. Therapies for peripheral joint disease in psoriatic arthritis. A systematic Review. J Rheum 2006;33:1-7.
  8. Eder L., Chandran V., Ueng J., et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis // Rheumatology (Oxford). -2010. - Vol. 49(7). - P. 1367-73.
  9. Saviola G., Abdi Ali L., Shams Eddin S., et al. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-monthopen randomizedpilot study//Rheumatology (Oxford). - 2007. - Vol. 46(6). -P. 994-98.
  10. Menter A., Korman N.J., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis // J. Am. Acad. Dermatol. - 2009. - Vol. 61. - P. 451-85.
  11. Pathirana D., Ormerod A.D., Saigag P., et al. European S3-guidelines on systemic treatment of psoriasis vulgaris // J. Eur. Acad. Dermatol. Venereol. - 2009. - P. 23. - P. 1-70.
  12. Ravindran V, Scott D.L., Choy E.H. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis // Ann. Rheum. Dis. - 2008.- Vol. 67. - P. 855-59.
  13. Ash Z, Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis // Ann. Rheum. Dis. -2012. -Vol. 71. - P. 319-26.
  14. Gladman D., Mease P., Choy E., et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT // Arthritis Res. Ther. -2010. -Vol. 12(3). - P. 113.
  15. Fraser A.D., van Kuijk A.W.R., Westhovens R., et al. A randomized, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis // Ann. Rheum. Dis. - 2005. - Vol. 64. - P. 859-64.
  16. Abu-Shakra M., Gladman D.D., Thorne J.C., et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome // J. Rheum. - 1995. - Vol. 2. - P. 241-45.
  17. Black R.L., O'Brien W.M., Vanscott E.J., et al. Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients // JAMA. -1964. - Vol. 189. - P. 743-47.
  18. Baranauskaite A., Raffayov H., Kungurov N., et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexatenaive patients: the RESPOND study // Ann. Rheum. Dis. - 2012. - Vol. 71(4). - P. 541-48.
  19. Espinoza L.R., Zakraoui L., Espinoza L.R. Psoriatic arthritis: clinical response and side effects to Methotrexate therapy// J. Rheum. - 1992. -Vol. 19. - P. 872-77.
  20. Combe B., Goupille P., Hamilton T.A., et al. Sulfasalazine in psoriatic arthritis: a randomized, multicenter, placebo - controlled study // Br. J. Rheum. - 1996. - Vol. 35. - P. 664-68.
  21. Salvarani C., Macchioni P., Olivieri I., et al. A Comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis // J. Rheum. - 2001. - Vol. 28. -P. 2274-82.
  22. Van Denderen J.C. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis // Ann. Rheum. Dis. - 2005. - Vol. 64(12). -P. 1761-64.
  23. Cuchacovich M., Soto L. Leflunomide decreases joint erosion and induces reparative changes in a patients with psoriatic arthritis // Ann. Rheum. Dis. - 2001. - Vol. 60. - P. 913-23.
  24. Kaltwasser J.P., Nash P., Gladman D.D., et al. Treatment of psoriatic arthritis study group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multionational, double-blind, randomized, placebocontrolled clinical trial// Arthr. Rheum. - 2004. - Vol. 50. - P. 1939-50.
  25. Macchioni P., Boiardi L., Cremonesi T., et al. The relationship between serum-soluble interleuikin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporine-A //Rheum. Int. - 1998. - Vol. 18. - P. 3327-53.
  26. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies// Ann. Rheum. Dis. - 2012. - Vol. 71. - P. 4-12.
  27. Ritchlin C.T., Kavanaugh A., Gladman D.D., et al. Treatment recommendations for psoriatic arthritis // Ann. Rheum. Dis. - 2009. - Vol. 68. -P. 1387-94.
  28. McInnes I., Kavanaugh A., Gottlieb A., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebocontrolled PSUMMIT 1 trial. - Lancet 2013. [Epub ahead of print.]
  29. Kavanaugh A., Menter A., Mendelsohn A., et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebocontrolled, phase II trial//Curr. Med. Res. Opin. - 2010. - Vol. 26. - P. 2385-92.
  30. Gottlieb A., Narang K. Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential // Ther. Adv. Musculoskelet. Dis. - 2013. - Vol. 5(5). - P. 277-85.
  31. Kristensen L.E., Gulfe A., Saxne T., et al. Eficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register// Ann. Rheum. Dis. - 2008. -Vol. 67. - P. 364-69.
  32. Saad A.A., Ashcroft D.M., Watson K.D., et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register// Rheumatology (Oxford). - 2010. -Vol. 49. - P. 697-705.
  33. Glintborg B., Ostergaard M., Dreyer L., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor alpha therapy: results from the nationwide Danish DANBIO registry// Arthritis Rheum. - 2011. -Vol. 63. - P. 382-90.
  34. Mease P. Update on Treatment of Psoriatic Arthritis //Bulletin of the NYU Hospital for Joint Diseases. - 2012. - Vol. 70(3). - P. 167-71.
  35. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study// Arthritis Rheum. - 2009. - Vol. 60. - P. 976-86.
  36. Van der Heijde D., Sieper J., Maksymowych W.P., et al. Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis // Ann. Rheum. Dis. - 2011. - Vol. 70. - P. 905-08.
  37. Coates L.C.,Cawkwell L.S.,Ng N.W.,Bennett A.N., Bryer D.J., Fraser A.D., et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life expe-rience // Ann. Rheum. Dis. - 2008. - Vol. 67. -P. 717-19.
  38. Heiberg M.S., Koldingsnes W., Mikkelsen K., et al. The comparative one-year performance of antitumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study // Arthritis Rheum. - 2008. - Vol. 59. - P. 234-40.
  39. Thorlund K., Druyts E., Avina-Zubieta J., Mills E. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis // Biologics: Targets and Therapy. - 2012. - Vol. 6. -P. 417-27.
  40. Rozenblit M., Lebwohl M. New biologics for psoriasis and psoriatic arthritis // Dermatol. Ther. - 2009. - Vol. 22. - P. 56-60.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2013

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах